Syros Pharmaceuticals, Inc. (SYRS)

5,13 -0,07 (-1,35%) Börsenschluss: 04:00PM EDT

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive
4th Floor
Cambridge, MA 02140
United States
617 744 1340
https://www.syros.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 68

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Richard A. Young Ph.D.	Scientific Founder, Member of Scientific Advisory Board & Director	108,37k	N/A	1954
Dr. David A. Roth M.D.	Chief Medical Officer	679,52k	N/A	1963
Mr. Conley Chee	CEO, President & Director	N/A	N/A	1970
Dr. James E. Bradner M.D.	Founder	N/A	N/A	1972
Dr. Nathanael S. Gray Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Jason Haas	Chief Financial Officer	457,22k	N/A	1968
Ms. Karen Hunady M.S.	Director of Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Gerald E. Quirk Esq., J.D.	Chief Legal Officer & Head of Business Development	127,07k	N/A	1968
Ms. Lisa Roberts	Vice President of Human Resources	N/A	N/A	N/A
Ms. Kristin Stephens	Chief Development Officer	N/A	N/A	1973

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Syros Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 7, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.